| Allogene Therapeutics is a clinical stage immuno-oncology company focused on the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. Co.'s key product candidates, ALLO-501 and ALLO-501A, are engineered allogeneic CAR T cell therapies that target CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. In addition to its development of allogeneic CAR T cell product candidates, Co. is developing an anti-CD52 monoclonal antibody, ALLO-647, which is designed to be used prior to infusing its other product candidates as part of the lymphodepletion regimen. We show 13 historical shares outstanding datapoints in our ALLO shares outstanding history coverage, used to compute ALLO market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ALLO market cap history over the course of time is important for investors
interested in comparing ALLO's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ALLO versus a peer is one thing; comparing
ALLO market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ALLO can fluctuate over the course of history.
With this page we aim to empower investors researching ALLO by allowing them to research the ALLO market cap history.